Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2013

Rockland Acquires Epi-Plus Product Line

  • Rockland Immunochemicals acquired the Epi-Plus® antibody product line from 21st Century Biochemicals. Epi-Plus antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP). The company will market the Epi-Plus product line on its e-commerce website and through its existing global distribution network.

    "The acquisition of the Epi-Plus product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, president and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."

    Research in epigenetics has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 billion in 2012 and is expected to reach $8 billion by 2017, a five-year CAGR of 25%.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »